Cargando…
Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania
Nanotherapeutic agents (NTA) play a crucial role in clinical medicine, if their unique properties are well understood and well exploited. In this direction, we report synthesis and characterization of highly potent phytofabricated silver nanoparticles (AgNPs) using Sechium edule, which served the pu...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995914/ https://www.ncbi.nlm.nih.gov/pubmed/29891923 http://dx.doi.org/10.1038/s41598-018-27170-1 |
_version_ | 1783330704294150144 |
---|---|
author | Baranwal, Anupriya Chiranjivi, Adarsh Kumar Kumar, Ashutosh Dubey, Vikash Kumar Chandra, Pranjal |
author_facet | Baranwal, Anupriya Chiranjivi, Adarsh Kumar Kumar, Ashutosh Dubey, Vikash Kumar Chandra, Pranjal |
author_sort | Baranwal, Anupriya |
collection | PubMed |
description | Nanotherapeutic agents (NTA) play a crucial role in clinical medicine, if their unique properties are well understood and well exploited. In this direction, we report synthesis and characterization of highly potent phytofabricated silver nanoparticles (AgNPs) using Sechium edule, which served the purpose of both reducing and capping agent. The designed AgNPs were characterized using UV-Vis spectroscopy, XRD, FTIR, HR-TEM, and TGA techniques. The formation of AgNPs was also confirmed using electrochemistry, which to the best of our knowledge has never been reported before for biosynthesized nanoparticles. The antileishmanial potential of AgNPs was examined on the clinical isolates of Leishmania donovani promastigote cells in an in vitro experimental setting. A dose dependent killing activity of the AgNP was observed with an IC(50) value of 51.88 ± 3.51 µg/ml. These results were also compared using commercially available drug, miltefosine. Furthermore, the clinical applicability of AgNP, as antileishmanial agent was proven by testing them against normal mammalian monocyte cell line (U937). The results were statistically analyzed and no significant toxicity of AgNPs on the normal mammalian cells was observed. |
format | Online Article Text |
id | pubmed-5995914 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-59959142018-06-21 Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania Baranwal, Anupriya Chiranjivi, Adarsh Kumar Kumar, Ashutosh Dubey, Vikash Kumar Chandra, Pranjal Sci Rep Article Nanotherapeutic agents (NTA) play a crucial role in clinical medicine, if their unique properties are well understood and well exploited. In this direction, we report synthesis and characterization of highly potent phytofabricated silver nanoparticles (AgNPs) using Sechium edule, which served the purpose of both reducing and capping agent. The designed AgNPs were characterized using UV-Vis spectroscopy, XRD, FTIR, HR-TEM, and TGA techniques. The formation of AgNPs was also confirmed using electrochemistry, which to the best of our knowledge has never been reported before for biosynthesized nanoparticles. The antileishmanial potential of AgNPs was examined on the clinical isolates of Leishmania donovani promastigote cells in an in vitro experimental setting. A dose dependent killing activity of the AgNP was observed with an IC(50) value of 51.88 ± 3.51 µg/ml. These results were also compared using commercially available drug, miltefosine. Furthermore, the clinical applicability of AgNP, as antileishmanial agent was proven by testing them against normal mammalian monocyte cell line (U937). The results were statistically analyzed and no significant toxicity of AgNPs on the normal mammalian cells was observed. Nature Publishing Group UK 2018-06-11 /pmc/articles/PMC5995914/ /pubmed/29891923 http://dx.doi.org/10.1038/s41598-018-27170-1 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Baranwal, Anupriya Chiranjivi, Adarsh Kumar Kumar, Ashutosh Dubey, Vikash Kumar Chandra, Pranjal Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania |
title | Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania |
title_full | Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania |
title_fullStr | Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania |
title_full_unstemmed | Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania |
title_short | Design of commercially comparable nanotherapeutic agent against human disease-causing parasite, Leishmania |
title_sort | design of commercially comparable nanotherapeutic agent against human disease-causing parasite, leishmania |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995914/ https://www.ncbi.nlm.nih.gov/pubmed/29891923 http://dx.doi.org/10.1038/s41598-018-27170-1 |
work_keys_str_mv | AT baranwalanupriya designofcommerciallycomparablenanotherapeuticagentagainsthumandiseasecausingparasiteleishmania AT chiranjiviadarshkumar designofcommerciallycomparablenanotherapeuticagentagainsthumandiseasecausingparasiteleishmania AT kumarashutosh designofcommerciallycomparablenanotherapeuticagentagainsthumandiseasecausingparasiteleishmania AT dubeyvikashkumar designofcommerciallycomparablenanotherapeuticagentagainsthumandiseasecausingparasiteleishmania AT chandrapranjal designofcommerciallycomparablenanotherapeuticagentagainsthumandiseasecausingparasiteleishmania |